# Catarina E Hioe

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 35 papers | 1,034 citations | 430754 18 h-index | 477173 29 g-index |
| 41 all docs | 41 docs citations | 41 times ranked | 1791 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. PLoS Pathogens, 2022, 18, e1010183. | 2.1 | 8 |
| 2 | Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases. Vaccines, 2021, 9, 112. | 2.1 | 5 |
| 3 | Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. MBio, 2021, 12, . | 1.8 | 64 |
| 4 | Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2021, 223, 957-970. | 1.9 | 64 |
| 5 | Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Frontiers in Immunology, 2021, 12, 759688. | 2.2 | 29 |
| 6 | A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2020, 222, 1629-1634. | 1.9 | 27 |
| 7 | P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion. Journal of Virology, 2020, 94, . | 1.5 | 12 |
| 8 | Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes. PLoS Pathogens, 2020, 16, e1009185. | 2.1 | 14 |
| 9 | HIV-1 Envelope Glycan Composition as a Key Determinant of Efficient Virus Transmission via DC-SIGN and Resistance to Inhibitory Lectins. IScience, 2019, 21, 413-427. | 1.9 | 11 |
| 10 | Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. Scientific Reports, 2018, 8, 542. | 1.6 | 30 |
| 11 | Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines. Frontiers in Immunology, 2018, 9, 2441. | 2.2 | 22 |
| 12 | Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations. PLoS Pathogens, 2018, 14, e1006812. | 2.1 | 20 |
| 13 | Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins. PLoS ONE, 2018, 13, e0194498. | 1.1 | 12 |
| 14 | Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. Vaccine, 2017, 35, 1464-1473. | 1.7 | 15 |
| 15 | Short Communication: ManÎ±1-2Man-Binding Anti-HIV Lectins Enhance the Exposure of V2i and V3 Crown Neutralization Epitopes on the V1/V2 and V3 Hypervariable Loops of HIV-1 Envelope. AIDS Research and Human Retroviruses, 2017, 33, 941-945. | 0.5 | 10 |
| 16 | Differential effects of HIV transmission from monocyte-derived dendritic cells vs. monocytes to IL-17 + CD4 + T cells. Journal of Leukocyte Biology, 2017, 101, 339-350. | 1.5 | 3 |
| 17 | Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. Journal of Virology, 2016, 90, 10993-11006. | 1.5 | 33 |
| 18 | HIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell Activation. Journal of Virology, 2016, 90, 10513-10526. | 1.5 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies. PLoS ONE, 2015, 10, e0141233. | 1.1 | 10 |
| 20 | Distinct Mechanisms Regulate Exposure of Neutralizing Epitopes in the V2 and V3 Loops of HIV-1 Envelope. Journal of Virology, 2014, 88, 12853-12865. | 1.5 | 53 |
| 21 | Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. Vaccine, 2014, 32, 4916-4924. | 1.7 | 9 |
| 22 | Adenosine Deaminase Acting on RNA-1 (ADAR1) Inhibits HIV-1 Replication in Human Alveolar Macrophages. PLoS ONE, 2014, 9, e108476. | 1.1 | 19 |
| 23 | Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines. Vaccine, 2013, 31, 5413-5421. | 1.7 | 39 |
| 24 | Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine. Journal of AIDS & Clinical Research, 2012, 01, . | 0.5 | 9 |
| 25 | Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine, 2011, 29, 6736-6741. | 1.7 | 20 |
| 26 | Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine, 2011, 29, 9064-9074. | 1.7 | 37 |
| 27 | HIV Envelope gp120 Activates LFA-1 on CD4 T-Lymphocytes and Increases Cell Susceptibility to LFA-1-Targeting Leukotoxin (LtxA). PLoS ONE, 2011, 6, e23202. | 1.1 | 32 |
| 28 | Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes. PLoS ONE, 2010, 5, e10254. | 1.1 | 128 |
| 29 | The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine, 2009, 28, 352-360. | 1.7 | 51 |
| 30 | In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology, 2008, 372, 409-420. | 1.1 | 39 |
| 31 | Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Infectious Agents and Cancer, 2008, 3, 11. | 1.2 | 9 |
| 32 | The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry. Journal of the American Society for Mass Spectrometry, 2006, 17, 1560-1569. | 1.2 | 22 |
| 33 | Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. European Journal of Immunology, 2005, 35, 2541-2551. | 1.6 | 30 |
| 34 | Human Immunodeficiency Virus Type 1 Evades T-Helper Responses by Exploiting Antibodies That Suppress Antigen Processing. Journal of Virology, 2004, 78, 7645-7652. | 1.5 | 26 |
| 35 | Anti-CD4-Binding Domain Antibodies Complexed with HIV Type 1 Glycoprotein 120 Inhibit CD4+T Cell-Proliferative Responses to Glycoprotein 120. AIDS Research and Human Retroviruses, 2000, 16, 893-905. | 0.5 | 21 |